A Cochrane review [Abstract] 1 included 60 studies with a total of 11 698 subjects. Included were RCTs on systemic, intravenous or oral chemotherapy versus best supportive care (BSC), combination versus single-agent chemotherapy and different chemotherapy regimens in advanced gastric cancer.
Chemotherapy extended overall survival (OS) by approximately 6.7 months more than BSC (hazard ratio (HR) 0.3, 95% CI 0.24 to 0.55, 184 participants, three studies). Combination chemotherapy extended OS slightly (by an additional month) versus single-agent chemotherapy (HR 0.84, 95% CI 0.79 to 0.89, 4447 participants, 23 studies), which was partly counterbalanced by increased toxicity.
SOF Table http://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004064.pub4/full#CD004064-sec1-0001
Primary/Secondary Keywords